Screening for hemochromatosis in asymptomatic subjects with or without a family history

Archives of Internal Medicine

Volumn 166, Issue 3, 2006, Pages 294-301

  Powell, Lawrie W ^a   Dixon, Jeannette L ^a   Ramm, Grant A ^a   Purdie, David M ^a   Lincoln, Douglas J ^a   Anderson, Gregory J ^a   Subramaniam, V Nathan ^a   Hewett, David G ^a   Searle, Jeffrey W ^a   Fletcher, Linda M ^b   Crawford, Darrell H ^b   Rodgers, Helen ^d   Allen, Katrina J ^c   Cavanaugh, Juleen A ^d,e   Bassett, Mark L ^d,e  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d CANBERRA HOSPITAL   (Australia)

^e AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FAMILY HISTORY; FEMALE; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; IRON OVERLOAD; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; PHLEBOTOMY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCREENING; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; AUSTRALIA; BIOPSY; CHILD; COHORT STUDIES; FEMALE; FERRITINS; HEMOCHROMATOSIS; HOMOZYGOTE; HUMANS; IRON OVERLOAD; LIVER; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 32644445055     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.166.3.294     Document Type: Article

References (40)

1. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology. 1999;116:193-207.
2. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211-218.
3. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718-724.
4. Adams PC, Reboussin DM, Barton JC, et al. Hemochromaotis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769-1778.
5. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community screening to prevent HFE-associated hereditary haemochromatosis. Lancet. 2005;366:314-316.
6. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107-1119.
7. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36:1108-1115.
8. Milman N, Pedersen P, Ovesen L, Melsen GV, Fenger K. Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in 2501 ethnic Danes. Ann Hematol. 2004;83:654-657.
9. Bulaj ZJ, Ajoika RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000;343:1529-1535.
10. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology. 2000;31:1160-1164.
11. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: expectations based on a study of relatives of symptomatic probands. J Med Screen. 1996;3:171-177.
12. Halliday JW, Russo AM, Cowlishaw JL, Powell LW. Serum ferritin in diagnosis of haemochromatosis. Lancet. 1977;2:621-623.
13. Bassett ML, Halliday JW, Ferris RA, Powell LW. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology. 1984;87:628-633.
14. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet. 1996;14:249-251.
15. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early haemochromatosis and determination of the critical iron concentration associated with fibrosis. Hepatology. 1986;6:24-29.
16. Leggett BA, Halliday JW, Brown NN, Powell LW. Prevalence of hemochromatosis amongst asymptomatic Australians. Br J Haematol. 1990;74:525-530.
17. Searle JW, Kerr JFR, Halliday JW, Powell LW. Iron storage disease. In: Mac-Sween RM, Anthony PP, Scheuer PJ, eds. Pathology of the Liver. 2nd ed. Edinburgh, Scotland: Churchill Livingstone; 1987:257-272.
18. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372-374.
19. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122:281-289.
20. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol. 1973;26:770-772.
21. Wanless IR. Physioanatomic considerations. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. 8th ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1993:3-37.
22. Worwood M. Laboratory determinants of iron status. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. London, England: WB Saunders & Co; 1994:449-476.
23. Bothwell TH, Charlton RW, Cook JD, Finch CA. Iron Metabolism in Man. Oxford, England: Blackwell Scientific Publications, 1979:89.
24. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103:2914-2919.
25. Milman N, Pedersen P, a Steig T, Byg KE, Graudal N, Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol. 2001;80:737-744.
26. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evoluation of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc. 2004;79:309-313.
27. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology. 1997;25:162-166.
28. Adams PC. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis Am J Gastroenterol. 2001;96:567-569.
29. Sallie RW, Reed WD, Shilkin KB. Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic haemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis. Gut. 1991;32:207-210.
30. Yamashita C, Adams PC. Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin Gastroenterol Hepatol. 2003;1:388-391.
31. Leggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem. 1990;36:1350-1355.
32. Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. 2003;138:627-633.
33. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology. 1998;115:929-936.
34. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet. 2003;12:2241-2247.
35. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77-82.
36. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood. 2004;103:2835-2840.
37. Le Gac G, Scotet V, Ka C, et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet. 2004;13:1913-1918.
38. Fargion S, Valenti L, Dongiovanni P, Fracanzani AL. TNF-alpha promoter polymorphisms. Methods Mol Med. 2004;98:47-58.
39. Stickel F, Oesterreicher CH, Datz C, et al. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med. 2005;165:1815-1817.
40. Oesterreicher CH, Datz C, Stickel F, et al. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine. 2005;31:142-148.